Articles dans des revues avec comité de lecture (103)
  1. 49. Gilot, D., Migault, M., Bachelot, L., Journé, F., Rogiers, A., Donnou-Fournet, E., Mogha, A., Mouchet, N., Pinel-Marie, M. L., Mari, B., Montier, T., Correia, S., Gautron, A., Rambow, F., El Hajj, P., Ben Jouira, R., Tartare-Deckert, S., Marine, J.-C., Felden, B., Ghanem, G. E., & Galibert, M. D. (2017). A non-coding function of TYRP1 mRNA promotes melanoma growth. Nature cell biology, 19(11), 1348-1357. doi:10.1038/ncb3623
  2. 50. Zhang, Y., Guo, J., Yang, W., Goncalves, C., Rzymski, T., Dreas, A., Zyłkiewicz, E., Mikulski, M., Brzózka, K., Golas, A., Kong, Y., Ma, M., Huang, F., Huor, B., Guo, Q., Da Silva, S. D., Rivera-Torres, J., Cai, Y., Topisirovic, I., Su, J., Bijian, K., Alaoui-Jamali, M. A., Huang, S., Journé, F., Ghanem, G. E., Miller, W. W., & Del Rincón, S. S. (2017). MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. The Journal of clinical investigation, 127(11), 4179-4192. doi:10.1172/JCI91258
  3. 51. Arcolia, V., Boutry, S., Laurent, S., Saussez, S., Journé, F., Wattier, A., Leteurtre, E., Renaud, F., Gabius, H.-J., Remmelink, M., Decaestecker, C., & Rodriguez, A. (2017). Galectin-1 is a diagnostic marker involved in thyroid cancer progression. International journal of oncology, 51(3), 760-770. doi:10.3892/ijo.2017.4065
  4. 52. Najem, A., Krayem, M., Sales, F., Hussein, N., Badran, B., Robert, C., Awada, A., Journé, F., & Ghanem, G. E. (2017). P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. European journal of cancer, 83, 154-165. doi:10.1016/j.ejca.2017.06.033
  5. 53. Kindt, N., Saussez, S., Descamps, G., Seminerio, I., Bellier, J., Lechien, J., Mat, Q., Pottier, C., Delvenne, P. O., & Journé, F. (2017). High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma. Oral oncology, 67, 183-191. doi:10.1016/j.oraloncology.2017.02.023
  6. 54. Najar, M., Fayyad Kazan, H., Faour, W., Badran, B., Journé, F., & Lagneaux, L. (2017). Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response. Inflammation research, 66(2), 129-139. doi:10.1007/s00011-016-1000-8
  7. 55. Arcolia, V., Journé, F., Renaud, F., Leteurtre, E., Gabius, H.-J., Remmelink, M., & Saussez, S. (2017). Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncology Letters, 14(4), 4183-4189. doi:10.3892/ol.2017.6719
  8. 56. Kindt, N., Saussez, S., Descamps, G., Seminerio, I., Bellier, J., Lechien, J., Pottier, C., Larsimont, D., Journé, F., & Delvenne, P. O. (2016). Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas. Oral oncology, 62, 1-10. doi:10.1016/j.oraloncology.2016.08.016
  9. 57. Kindt, N., Journé, F., Laurent, G., & Saussez, S. (2016). Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets (Review). Oncology Letters, 12(4), 2247-2253. doi:10.3892/ol.2016.4929
  10. 58. Brouwers, B., Bechter, O., Bailur, J. K., Kenis, C., Laenen, A., Schöffski, P., Pawelec, G., Journé, F., Ghanem, G. E., Wildiers, H., Hatse, S., Dal Lago, L., Neven, P., Vuylsteke, P., Dalmasso, B., Debrock, G., Van Den Bulck, H., & Smeets, A. (2016). The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget, 7(21), 29977-29988. doi:10.18632/oncotarget.8796
  11. 59. Krayem, M., Journé, F., Wiedig, M., Morandini, R., Najem, A., Sales, F., van Kempen, L., Sibille, C., Awada, A., Marine, J.-C., & Ghanem, G. E. (2016). P53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. European journal of cancer, 55, 98-110. doi:10.1016/j.ejca.2015.12.002
  12. 60. Descamps, G., Karaca, Y., Lechien, J., Kindt, N., Decaestecker, C., Remmelink, M., Larsimont, D., Andry, G., Hassid, S., Rodriguez, A., Khalifé, M., Journé, F., & Saussez, S. (2016). Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. Journal of cancer research and clinical oncology, 142(10), 2185-2196. doi:10.1007/s00432-016-2203-7
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 Suivant >>